A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
An Open-label, Adaptive, Repeat-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Iloperidone Long-acting Injection (LAI) in Patients With Schizophrenia
Sponsor: Vanda Pharmaceuticals
A PHASE1 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Vanda Pharmaceuticals and has accumulated 6 data snapshots since 2021. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jul 2022 — Jul 2023 [monthly]
Recruiting PHASE1
-
May 2021 — Jul 2022 [monthly]
Recruiting PHASE1
▶ Show 1 earlier version
-
Feb 2021 — May 2021 [monthly]
Recruiting PHASE1
First recorded
Jan 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vanda Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .